ArticleNature2020
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,370 papers.
0numbers the graph read from it
0cells of the map it votes in
1,370citing papers in PubMed
48.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of a Combination of Two Anti-SARS-CoV-2 mAbs (C144-LS and C135-LS) in Healthy Volunteers
Monitoring Serologic Response to SARS-COV-2 / Coronavirus Disease 2019 (COVID-19) in Children, Adolescents, and Young Adults Receiving Biologic Therapies (RECONN)
Who cites it
1,370 citing papers in PubMed, 2,126 citations in OpenAlex.
- Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.Journal of virology · 2025Trial
- SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.The Journal of infectious diseases · 2024Trial
- Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster.Microbiology spectrum · 2024Trial
- Antibody-mediated SARS-CoV-2 entry and conformational regulation.Microbiology spectrum · 2026Article
- Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity.bioRxiv : the preprint server for biology · 2026Article
- Serum Escape Landscape of SARS-CoV-2 Omicron JN.1 and XEC RBD Under COVID-19 Vaccine Breakthrough Immunity in China.Microorganisms · 2026Article
- Rapid discovery of monoclonal antibodies via high-throughput single BCR affinity sequencing.Nucleic acids research · 2026Article
- The SARS-CoV-2 S2'-helix compared to stem helix confers higher genetic barrier to antibody resistance.PLoS pathogens · 2026Article
- Charge-driven antiviral responses enhance autoreactivity in severe COVID-19.Research square · 2026Article
- Viral syncytia evolve to resist interferon.Nature communications · 2026Article
- Article
- Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS-CoV-2 Omicron Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Biophysical properties of IgD determine thresholds for self-tolerance and selection into germinal centers.bioRxiv : the preprint server for biology · 2026Article
- Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid.PLoS pathogens · 2026Article
- mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh.Vaccines · 2026Article
- Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.Scientific reports · 2026Article
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Systems-Scale Structural Modeling Reveals the Germline Architecture of Immunodominance.bioRxiv : the preprint server for biology · 2026Article
- From Single Cells to Silicon: Emerging Technologies Transforming Monoclonal Antibody Discovery.Antibodies (Basel, Switzerland) · 2026Review
1,310 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
46 authors at 6 institutions in 2 countries.
Davide F Robbiani *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. drobbiani@irb.usi.ch.ORCID http://orcid.org/0000-0001-7379-3484
Christian Gaebler *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0001-7295-8128
Frauke Muecksch *Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-0132-5101
Julio C C Lorenzi *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-2492-3961
Zijun Wang *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Alice Cho *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Marianna Agudelo *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Christopher O Barnes *Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Anna Gazumyan *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Shlomo Finkin *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Thomas Hägglöf *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Thiago Y Oliveira *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Charlotte Viant *Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Arlene HurleyHospital Program Direction, The Rockefeller University, New York, NY, USA.
Hans-Heinrich HoffmannLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Katrina G MillardLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Rhonda G KostCenter for Clinical Translational Science, The Rockefeller University, New York, NY, USA.
Melissa CipollaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Kristie GordonLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Filippo BianchiniLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Spencer T ChenLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Victor RamosLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Roshni PatelLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Juan DizonLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Irina ShimeliovichLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Pilar MendozaLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Harald HartwegerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-1118-1818
Lilian NogueiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Maggi PackLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Jill HorowitzLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
Fabian SchmidtLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Yiska WeisblumLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Eleftherios MichailidisLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Alison W AshbrookLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-1114-1426
Eric WaltariChan Zuckerberg Biohub, San Francisco, CA, USA.
John E PakChan Zuckerberg Biohub, San Francisco, CA, USA.
Kathryn E Huey-TubmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Nicholas KorandaDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Pauline R HoffmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Anthony P WestDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. bjorkman@caltech.edu.ORCID http://orcid.org/0000-0002-2277-3990
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. nussen@rockefeller.edu.
Rockefeller University · USCalifornia Institute of Technology · USChan Zuckerberg Initiative (United States) · USHoward Hughes Medical Institute · USRockefeller University Hospital · USUniversità della Svizzera italiana · CH
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0MVirus TransmissionP50AI150464 · NIAID · UNIVERSITY OF UTAH · PI HOPE, THOMAS · 2019 to 2021
$14.9MOvercoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3MVirology CoreP01AI138938 · NIAID · ROCKEFELLER UNIVERSITY · PI BJORKMAN, PAMELA J · 2018 to 2022
$8.4MType I interferon-stimulated genes and the antiviral immune responseR01AI091707 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2011 to 2020
$5.5MDiscovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9MImmunity and Infectious DiseaseT32AI070084 · NIAID · ROCKEFELLER UNIVERSITY · PI Michel C Nussenzweig · 2008 to 2026
$3.3MRetrovirus Restriction by Trima5alphaR01AI064003 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI BIENIASZ, PAUL D. · 2005 to 2009
$2.1MHoward Hughes Medical InstituteNCATS NIH HHS UL1 TR001866NIAID NIH HHS P01 AI138938NIAID NIH HHS P50 AI150464NIAID NIH HHS R01 AI078788NIAID NIH HHS R01 AI091707NIAID NIH HHS R37 AI064003NIAID NIH HHS T32 AI070084NIAID NIH HHS U19 AI111825
Abstract
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2
Indexed as
AdolescentAdultAgedAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody SpecificityBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 VaccinesEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04700163ClinicalTrials.gov
NCT04838834ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.